PACB vs PEN Stock Comparison
PEN currently leads PACB in this stock comparison, with AIQ scores of 66 vs 48. The clearest difference is risk resilience, while PACB has the stronger momentum profile.
What is the main difference between PACB and PEN?
PEN leads the current stock comparison as Penumbra, Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Pacific Biosciences of California, Inc. vs Penumbra, Inc.
PEN leads
PEN leads by 18 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 23 points over 30 sessions.
Stable: 4 of 5 evidence groups support PEN, its lead is narrowing, and its current signal state is conflicted.
Pacific Biosciences of California, Inc.
Penumbra, Inc.
The Algovestiq AIQ Score currently favors PEN over PACB, 66 versus 48 as of Nov 18, 2026. PEN's advantage is driven primarily by stronger risk resilience and quality, while PACB holds the stronger momentum profile. PEN also shows the stronger technical structure relative to its 50-day moving average. 4 of 5 covered evidence groups favor PEN today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. PEN lead: Weakening — the AIQ differential moved from 23 to 18 points over 30 sessions.
Compare Pacific Biosciences of California, Inc. and Penumbra, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare PACB and PEN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience24 vs 92PEN +68
- Quality32 vs 78PEN +46
- Momentum84 vs 56PACB +28
- Value23 vs 48PEN +25
4 of 5 evidence groups favor PEN. PEN’s edge is concentrated in risk resilience and quality; PACB keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Value -1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- Stochastic Oversold Bounce — bullish, momentum, short horizon
Largest factor move: Momentum +2, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.60x)
PEN's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — PACB and PEN both carry a full feed there.
The central trade-off
PEN (Penumbra, Inc.): the stronger current systematic profile, led by risk resilience and quality.
PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 114.1% against 10.9%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
PENPEN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PENPEN on combined revenue and EPS growth.
Value
PENPEN on the peer-relative Value factor, by 25 points.
Momentum
PACBPACB on the Momentum factor, by 28 points.
Lower downside
PENPEN on Risk Resilience, by 68 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | PACB | PEN | Note |
|---|---|---|---|
| Implied upside to target | +5.2% | — | Level |
| Target dispersion | +59.7% | — | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 8 | 17 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 5 covered evidence groups favor PEN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | PEN | 48 vs 66 |
| Fundamentals | PENon balance | revenue growth 4% vs 5.2%; EPS growth 14.3% vs 21.6%; TTM ROE 61.7% vs 2.7%; gross margin 34.5% vs 68%; operating margin -99.6% vs 12.1% — PEN takes 4 of 5 decided legs, not all of them |
| Valuation | PEN | Value 23 vs 48 |
| Technicals | PACB | Price vs 50-day -8.7% vs 0.1%; vs 200-day 22.4% vs -1.5% |
| Risk Resilience | PEN | Risk Resilience 24 vs 92 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PACB and PEN and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 18 points. (supports the conclusion holding)
- 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PEN.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18PEN lead: Weakening — the AIQ differential moved from 23 to 18 points over 30 sessions.
- Today
- PEN +18
- 48 vs 66
- 7 sessions ago
- PEN +17
- 49 vs 66
- 30 sessions ago
- PEN +23
- 44 vs 67
- 90 sessions ago
- PEN +31
- 30 vs 61
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 3 bearish / 1 neutral, conflicted
Only PACB
- Golden Cross Active — bullish, trend, long horizon (25.22%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (14.16%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- Stochastic Oversold Bounce — bullish, momentum, short horizon
2 bullish / 3 bearish / 4 neutral, conflicted
Only PEN
- Bollinger Band Squeeze — neutral, volatility, short horizon (2.5%)
- Death Cross Active — bearish, trend, long horizon (1.74%)
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Contraction - Coiling — neutral, volatility, short horizon (0.79%)
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-2.7%)
- EMA Ribbon Compression — neutral, trend, medium horizon
Both carry 3 more signals that do not separate them: EMA Ribbon Expansion Bullish, Low Volume Rally Warning, MACD Histogram Expanding Bearish.
PEN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.47%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PACB closes the Risk Resilience gap — currently 68 points behind, the largest single contributor to PEN's edge.
- 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3PEN's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
- 4The narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 18-point move would eliminate PEN's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PEN leads on balance| Metric | PACB | PEN |
|---|---|---|
| Revenue growth (YoY) | 4% | 5.2% |
| EPS growth (YoY) | 14.3% | 21.6% |
| Gross margin | 34.5% | 68% |
| Operating margin | -99.6% | 12.1% |
| Return on equity (TTM) | 61.7% | 2.7% |
| Debt to equity | -11.49 | 0.13 |
Performance
PACB leads 4 of 6 windows| Metric | PACB | PEN |
|---|---|---|
| 1 week (5 sessions) | -13.1% | 0.5% |
| 1 month (20 sessions) | 13.3% | 0% |
| 3 months (63 sessions) | 62% | -1.9% |
| 6 months (126 sessions) | 75% | -0.4% |
| Year to date | 4.8% | 3.2% |
| 1 year (252 sessions) | 12.6% | 14.5% |
Technicals
PACB has the stronger structure| Metric | PACB | PEN |
|---|---|---|
| RSI (14) | 43.1 | 49.5 |
| ADX (14) | 27.4 | 17 |
| Price vs 50-day | -8.7% | 0.1% |
| Price vs 200-day | 22.4% | -1.5% |
| Volatility (1M, annualized) | 114.1% | 10.9% |
Risk
PEN is the more resilient| Metric | PACB | PEN |
|---|---|---|
| Beta | 2.1 | 0.19 |
| Sharpe ratio | 0.61 | 0.62 |
| Sortino ratio | 0.96 | 1.15 |
| Max drawdown | -58.4% | -12.2% |
| Current drawdown | -32.4% | -10.7% |
| Annualized volatility | 93.5% | 19.5% |
| Value at risk (95%) | -9% | -0.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, PACB or PEN?
On the Algovestiq AIQ Score, PEN is the stronger of the two as of Nov 18, 2026, scoring 66 against PACB's 48. The edge comes from risk resilience and quality. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is PACB or PEN the better buy right now?
PEN carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Stable — 4 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor PEN over PACB?
The composite weights Quality, Value, Momentum and Risk Resilience. PEN leads Risk Resilience by 68 points; PEN leads Quality by 46 points; PACB leads Momentum by 28 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, PACB or PEN?
Analyst price targets imply +5.2% upside for PACB and not covered for PEN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, PACB or PEN?
PEN is the better-valued of the two on the peer-relative Value factor. PEN on the peer-relative Value factor, by 25 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, PACB or PEN?
PEN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, PACB or PEN?
PACB on the Momentum factor, by 28 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, PACB or PEN?
PEN is the more resilient of the two, so the other name carries the higher downside risk. PEN on Risk Resilience, by 68 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is PACB more profitable than PEN?
The profitability evidence is mixed: gross margin 34.5% vs 68%; operating margin -99.6% vs 12.1%; ttm roe 61.7% vs 2.7%. PACB leads on one measure and PEN on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is PEN's lead over PACB getting stronger or weaker?
PEN lead: Weakening — the AIQ differential moved from 23 to 18 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.
What would change the PACB vs PEN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Risk Resilience gap — currently 68 points behind, the largest single contributor to PEN's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; PEN's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 18-point move would eliminate PEN's advantage entirely.
What do the current signals say about PACB and PEN?
PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. PEN: 2 bullish / 3 bearish / 4 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PACB is Golden Cross Active (bullish, long horizon). On PEN it is Death Cross Active (bearish, long horizon).
Compare PACB and PEN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.